

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9960)

VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This is a voluntary announcement made by Kindstar Globalgene Technology, Inc. (the “**Company**”) to provide its shareholders (the “**Shareholders**”) and potential investors with information in relation to the latest developments regarding the Company. Capitalized terms used herein shall have the same meanings as defined in the prospectus of the Company dated June 29, 2021 (the “**Prospectus**”) unless the context requires otherwise.

Share Repurchase

Pursuant to the repurchase mandate granted to the directors (the “**Directors**”) of the Company by way of written resolutions of all Shareholders passed on June 22, 2021, the Directors were given a general unconditional mandate to exercise all powers of the Company to repurchase shares (the “**Shares**”) of the Company with the aggregate number of Shares to be repurchased by the Company not exceeding 10% of the number of issued Shares immediately following the completion of the Global Offering (excluding any Shares which may fall to be issued pursuant to the exercise of the Over-allotment Option, any additional Shares to be issued pursuant to the Pre-IPO Stock Incentive Plans or any Shares to be issued pursuant to the Post-IPO Share Schemes) (the “**Repurchase Mandate**”). The Repurchase Mandate will expire at the earliest of (i) the conclusion of the next annual general meeting of our Company, and (ii) the date when it is varied or revoked by an ordinary resolution of our Shareholders in general meeting. Details of the Repurchase Mandate are set out in the Prospectus.

On November 5, 2021, the board of Directors (the “**Board**”) formally resolved to authorize the executive Directors to utilize the Repurchase Mandate to repurchase Shares in the open market from time to time as appropriate. The Company may, subject to market conditions, make repurchase as appropriate.

The Company will exercise the Repurchase Mandate in compliance with the Articles of Association of the Company, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Act of the Cayman Islands and all applicable laws and regulations to which the Company is subject to.

The Company will finance the share repurchase with its internal resources.

The Board believes that a share repurchase in the present conditions demonstrates the Company's confidence in its own business outlook and prospects and would, in the long term, benefit the Company and create value to the Shareholders. The Board believes that the current internal financial resources of the Company would enable it to implement the share repurchase while maintaining a solid financial position. The share repurchase shall not result in the number of the Shares held by the public falling below the relevant minimum percentage prescribed by the Listing Rules. The Company will subsequently cancel the repurchased Shares.

The Company considers that a share repurchase reflects the Company's confidence in its current and long-term business outlook driven by its scalable business model with a proven track record, strong proprietary R&D and business development capability.

Shareholders and potential investors should note that any repurchase may be done subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.

By order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, November 5, 2021

As of the date of this announcement, the Board comprises Dr. Huang Shiang, Mr. Tu Zanbing and Ms. Chai Haijie as executive Directors, Mr. Huang Zuie-Chin, Mr. Peng Wei and Ms. Huang Lu as non-executive Directors, and Dr. Yao Shanglong, Dr. Xia Xinping and Mr. Gu Huaming as independent non-executive Directors.